Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CLN2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA576765
Description
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
This gene encodes a member of the sedolisin family of serine proteases. The protease functions in the lysosome to cleave N-terminal tripeptides from substrates, and has weaker endopeptidase activity. It is synthesized as a catalytically-inactive enzyme which is activated and auto-proteolyzed upon acidification. Mutations in this gene result in late-infantile neuronal ceroid lipofuscinosis, which is associated with the failure to degrade specific neuropeptides and a subunit of ATP synthase in the lysosome.
Specifications
CLN2 | |
Polyclonal | |
Unconjugated | |
TPP1 | |
cell growth-inhibiting gene 1 protein; ceroid-lipofuscinosis, neuronal 2; CLN 2; CLN2; GIG 1; GIG1; growth-inhibiting protein 1; LPIC; lysosomal pepstatin insensitive protease; lysosomal pepstatin-insensitive protease; MGC21297; SCAR7; TPP 1; TPP I; Tpp1; TPP-1; TPPI; TPP-I; Tripeptidyl aminopeptidase; tripeptidyl peptidase 1; tripeptidyl peptidase I; tripeptidyl peptidase-I; tripeptidyl-peptidase 1; Tripeptidyl-peptidase I; UNQ267/PRO304 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
1200, 12751 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.2 | |
O14773, O89023 | |
TPP1 | |
Recombinant full length Human CLN2. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction